UK Company offers solution to the world’s growing omega-3 demand
May 4, 2004 – Staffs, UK – In response to the growing global demand of omega-3 and 6 lipids in pharmaceuticals and nutraceuticals, Croda Health Care has more than doubled the manufacturing capacity of their high purity, high potency omega-3 and 6 lipids at a new plant in Staffs, UK.
Croda’s significant production expansion and established manufacturing expertise provide a solution to the current shortage of high-quality omega-3 and 6 concentrates. The new plant, built to the latest pharmaceutical standards (ICHQ7a, GMP API), employs advanced production technologies and comes on stream Q2 2004. “This development forms the first phase of our expansion programme and further investment is planned to support continuing market demand for our high purity lipids,” said Dr Keith Layden, Managing Director – Health and Personal Care.
Croda Health Care is proud to lead the way in purity standards for omega-3 and 6 fatty acids, offering an extensive range of pharmaceutical-grade lipid concentrates that target health issues such as heart, joint, brain, eye and skin health.
As positive research continues to be released on the health benefits of these omegas -particularly for heart and mental health - consumer awareness has risen and media attention has increased. Croda’s advanced supply will ease demand of the company’s optimum quality omega-3 and 6 lipids, which are distributed in N America by Bioriginal Food & Science Corp. Canada.